Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment

Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment
·1 min read

Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer will pay $68.50 a share in cash for Global Blood Therapeutics, which has one of few approved treatments for sickle-cell disease, a painful inherited blood disorder that most affects people of African, Middle Eastern and South Asian descent. The acquisition "complements and further enhances Pfizer's more than 30-y